Effects of antidepressant treatment on neuroactive steroids in major depression

Elena Romeo, Andreas Ströhle, Gianfranco Spalletta, Flavia Di Michele, Bettina Hermann, Florian Holsboer, Augusto Pasini, Rainer Rupprecht

Research output: Contribution to journalArticle

Abstract

Objective: There is evidence from animal studies that fluoxetine may enhance the concentrations of neuroactive steroids. Therefore, the authors investigated whether clinically effective treatment with antidepressants may alter the concentrations of neuroactive steroids in patients suffering from a major depressive episode. Method: In the first study, eight drug-naive outpatients with major depression were studied during treatment with fluoxetine. In a complementary study, 11 inpatients with major depression were studied during a severe depressive episode and after recovery following treatment with different antidepressants. Plasma samples were quantified for neuroactive steroids by means of a highly sensitive and specific combined gas chromatography/mass spectrometry analysis. Results: During depression, there was a significant decrease in 3α, 5α-tetrahydroprogesterone (3α, 5α-THP) and 3α, 5β-THP concentrations, both of which are positive modulators of the γ-aminobutyric acid(A) receptor, and a concomitant increase in 3β, 5α-THP levels. This dysequilibrium of neuroactive steroids could be corrected by treatment with different antidepressants. Conclusions: These results provide the first clinical evidence of a possible role of neuroactive steroids in successful antidepressant therapy.

Original languageEnglish
Pages (from-to)910-913
Number of pages4
JournalAmerican Journal of Psychiatry
Volume155
Issue number7
Publication statusPublished - 1998

Fingerprint

Antidepressive Agents
Steroids
Fluoxetine
Aminobutyrates
Therapeutics
Gas Chromatography-Mass Spectrometry
Inpatients
Outpatients
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Romeo, E., Ströhle, A., Spalletta, G., Di Michele, F., Hermann, B., Holsboer, F., ... Rupprecht, R. (1998). Effects of antidepressant treatment on neuroactive steroids in major depression. American Journal of Psychiatry, 155(7), 910-913.

Effects of antidepressant treatment on neuroactive steroids in major depression. / Romeo, Elena; Ströhle, Andreas; Spalletta, Gianfranco; Di Michele, Flavia; Hermann, Bettina; Holsboer, Florian; Pasini, Augusto; Rupprecht, Rainer.

In: American Journal of Psychiatry, Vol. 155, No. 7, 1998, p. 910-913.

Research output: Contribution to journalArticle

Romeo, E, Ströhle, A, Spalletta, G, Di Michele, F, Hermann, B, Holsboer, F, Pasini, A & Rupprecht, R 1998, 'Effects of antidepressant treatment on neuroactive steroids in major depression', American Journal of Psychiatry, vol. 155, no. 7, pp. 910-913.
Romeo E, Ströhle A, Spalletta G, Di Michele F, Hermann B, Holsboer F et al. Effects of antidepressant treatment on neuroactive steroids in major depression. American Journal of Psychiatry. 1998;155(7):910-913.
Romeo, Elena ; Ströhle, Andreas ; Spalletta, Gianfranco ; Di Michele, Flavia ; Hermann, Bettina ; Holsboer, Florian ; Pasini, Augusto ; Rupprecht, Rainer. / Effects of antidepressant treatment on neuroactive steroids in major depression. In: American Journal of Psychiatry. 1998 ; Vol. 155, No. 7. pp. 910-913.
@article{e4509586fe814a02934e840d55448250,
title = "Effects of antidepressant treatment on neuroactive steroids in major depression",
abstract = "Objective: There is evidence from animal studies that fluoxetine may enhance the concentrations of neuroactive steroids. Therefore, the authors investigated whether clinically effective treatment with antidepressants may alter the concentrations of neuroactive steroids in patients suffering from a major depressive episode. Method: In the first study, eight drug-naive outpatients with major depression were studied during treatment with fluoxetine. In a complementary study, 11 inpatients with major depression were studied during a severe depressive episode and after recovery following treatment with different antidepressants. Plasma samples were quantified for neuroactive steroids by means of a highly sensitive and specific combined gas chromatography/mass spectrometry analysis. Results: During depression, there was a significant decrease in 3α, 5α-tetrahydroprogesterone (3α, 5α-THP) and 3α, 5β-THP concentrations, both of which are positive modulators of the γ-aminobutyric acid(A) receptor, and a concomitant increase in 3β, 5α-THP levels. This dysequilibrium of neuroactive steroids could be corrected by treatment with different antidepressants. Conclusions: These results provide the first clinical evidence of a possible role of neuroactive steroids in successful antidepressant therapy.",
author = "Elena Romeo and Andreas Str{\"o}hle and Gianfranco Spalletta and {Di Michele}, Flavia and Bettina Hermann and Florian Holsboer and Augusto Pasini and Rainer Rupprecht",
year = "1998",
language = "English",
volume = "155",
pages = "910--913",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "7",

}

TY - JOUR

T1 - Effects of antidepressant treatment on neuroactive steroids in major depression

AU - Romeo, Elena

AU - Ströhle, Andreas

AU - Spalletta, Gianfranco

AU - Di Michele, Flavia

AU - Hermann, Bettina

AU - Holsboer, Florian

AU - Pasini, Augusto

AU - Rupprecht, Rainer

PY - 1998

Y1 - 1998

N2 - Objective: There is evidence from animal studies that fluoxetine may enhance the concentrations of neuroactive steroids. Therefore, the authors investigated whether clinically effective treatment with antidepressants may alter the concentrations of neuroactive steroids in patients suffering from a major depressive episode. Method: In the first study, eight drug-naive outpatients with major depression were studied during treatment with fluoxetine. In a complementary study, 11 inpatients with major depression were studied during a severe depressive episode and after recovery following treatment with different antidepressants. Plasma samples were quantified for neuroactive steroids by means of a highly sensitive and specific combined gas chromatography/mass spectrometry analysis. Results: During depression, there was a significant decrease in 3α, 5α-tetrahydroprogesterone (3α, 5α-THP) and 3α, 5β-THP concentrations, both of which are positive modulators of the γ-aminobutyric acid(A) receptor, and a concomitant increase in 3β, 5α-THP levels. This dysequilibrium of neuroactive steroids could be corrected by treatment with different antidepressants. Conclusions: These results provide the first clinical evidence of a possible role of neuroactive steroids in successful antidepressant therapy.

AB - Objective: There is evidence from animal studies that fluoxetine may enhance the concentrations of neuroactive steroids. Therefore, the authors investigated whether clinically effective treatment with antidepressants may alter the concentrations of neuroactive steroids in patients suffering from a major depressive episode. Method: In the first study, eight drug-naive outpatients with major depression were studied during treatment with fluoxetine. In a complementary study, 11 inpatients with major depression were studied during a severe depressive episode and after recovery following treatment with different antidepressants. Plasma samples were quantified for neuroactive steroids by means of a highly sensitive and specific combined gas chromatography/mass spectrometry analysis. Results: During depression, there was a significant decrease in 3α, 5α-tetrahydroprogesterone (3α, 5α-THP) and 3α, 5β-THP concentrations, both of which are positive modulators of the γ-aminobutyric acid(A) receptor, and a concomitant increase in 3β, 5α-THP levels. This dysequilibrium of neuroactive steroids could be corrected by treatment with different antidepressants. Conclusions: These results provide the first clinical evidence of a possible role of neuroactive steroids in successful antidepressant therapy.

UR - http://www.scopus.com/inward/record.url?scp=2642677680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642677680&partnerID=8YFLogxK

M3 - Article

C2 - 9659856

AN - SCOPUS:2642677680

VL - 155

SP - 910

EP - 913

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 7

ER -